This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-21 and is reviewed periodically as new material appears.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== FEMA === In April, the Federal Emergency Management Agency denied an extension of benefits for areas in Georgia and North Carolina which had been hit by Hurricane Helene in September 2024. Tornadoes hit parts the state of Mississippi in March and a major disaster declaration by the federal government took more than two months, even at the request of Republican governor Tate Reeves of Mississippi. On May 23, the Trump administration approved disaster aid for areas within 8 states including Mississippi, as well as Nebraska, Iowa, Missouri, Kansas, Arkansas, Oklahoma, and Texas.
== Sources == Johnson, Daniel; Hashaikeh, Raed; Hilal, Nidal (2021). "Basic principles of osmosis and osmotic pressure". In Hilal, Nidal; Ismail, Ahmad Fauzi; Khayet, Mohamed; Johnson, Daniel (eds.). Osmosis Engineering. Elsevier. pp. 1–15. doi:10.1016/B978-0-12-821016-1.00011-5. ISBN 978-0-12-821016-1.
Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes (T2D) and for weight loss. Tirzepatide is administered via subcutaneous injections (under the skin). It is sold in several countries under the brand name Mounjaro for T2D treatment. In the United States, it is sold under the brand name Zepbound for weight loss and for the treatment of obstructive sleep apnea. The most common side effects of tirzepatide include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain. In 2023, tirzepatide was the 110th-most commonly prescribed medication in the United States, with more than 6 million prescriptions.
Sources: en.wikipedia.org
=== Pandemics, disinfectants and healthcare systems === Increased antibiotic use during the early waves of the COVID-19 pandemic may exacerbate this global health challenge. Moreover, pandemic burdens on some healthcare systems may contribute to antibiotic-resistant infections. The use of disinfectants such as alcohol-based hand sanitizers, and antiseptic hand wash may also have the potential to increase antimicrobial resistance. Overuse of disinfectants can lead to mutations that induce antimicrobial resistance. On the other hand, "increased hand hygiene, decreased international travel, and decreased elective hospital procedures may have reduced AMR pathogen selection and spread in the short term" during the COVID-19 pandemic. Critically ill patients are prone to infections, and because of that, they often require antimicrobials. The more antimicrobials, the more resistance one becomes to it. Antimicrobial resistance (AMR) significantly strains healthcare systems and national economies. The World Bank estimates that by 2050, AMR could increase healthcare costs by around US$1 trillion and cause global economic losses of US$1–3.4 trillion annually by 2030. Resistant infections are harder to treat, often requiring longer hospital stays, additional tests, and stronger, more expensive medications, placing extra pressure on hospitals and health systems, especially during pandemics. A 2024 United Nations High-Level Meeting on AMR has pledged to reduce deaths associated with bacterial AMR by 10% over the next six years.
In podzol soils, after conversion of softwood to hardwood forest or after earthworm invasion, these animals can obliterate the characteristic banded appearance of the soil profile by mixing the organic (LFH), eluvial (E) and upper illuvial (B) horizonss to create a single dark Ap horizon. Earthworms accelerate nutrient cycling in the soil-plant system through fragmention and mixing, physical grinding and chemical digestion of plant debris. However, the earthworm's existence cannot be taken for granted. Dr. W. E. Shewell-Cooper observed "tremendous numerical differences between adjacent gardens", and worm populations are affected by a host of environmental factors, many of which can be influenced by good management practices on the part of the gardener or farmer. Darwin estimated that arable land contains up to 53,000 per acre (130,000/ha) of worms, but more recent research has produced figures suggesting that even poor soil may support 250,000 per acre (620,000/ha), whilst rich fertile farmland may have up to 1,750,000 per acre (4,300,000/ha), meaning that the weight of earthworms beneath a farmer's soil could be greater than that of the livestock upon its surface. Richly organic topsoil populations of earthworms are much higher, averaging 500 per square metre (46/sq ft) and up to 400 g/m2, such that, for the 7 billion of us, each person alive today has support of 7 million earthworms. The ability to break down organic materials and excrete concentrated nutrients makes the earthworm a functional contributor in restoration projects.
For much of the 19th century the chainsaw was a useful surgical instrument, but it was superseded in 1894 by the Gigli twisted-wire saw, which was substantially cheaper to manufacture, and gave a quicker, narrower cut, without risk of breaking and being entrapped in the bone. A precursor of the chainsaw familiar today in the timber industry was another medical instrument developed around 1830, by German precision mechanic and orthopaedist Bernhard Heine. This instrument, the osteotome, had links of a chain carrying small cutting teeth with the edges set at an angle; the chain was moved around a guiding blade by turning the handle of a sprocket wheel. As the name implies, this was used to cut bone.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.